REGN vs. TMO: Regeneron Pharmaceuticals vs. Thermo Fisher Scientific Stock Comparison

Company Profile

Regeneron Pharmaceuticals (REGN) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Regeneron Pharmaceuticals (REGN) at 14.95% and Thermo Fisher Scientific (TMO) at 13.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Thermo Fisher Scientific (TMO) at 14.94% also retains a top-quartile share.

Both Regeneron Pharmaceuticals (REGN) at 40.46% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Regeneron Pharmaceuticals (REGN) at 8.19% and Thermo Fisher Scientific (TMO) at 7.32% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TMO.

Regeneron Pharmaceuticals (REGN) at 0.08 carries an industry-typical debt-to-equity mix, while Thermo Fisher Scientific (TMO) at 0.75 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Regeneron Pharmaceuticals (REGN) at 0.41% and Thermo Fisher Scientific (TMO) at 0.27% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Regeneron Pharmaceuticals (REGN) at 8.18% and Thermo Fisher Scientific (TMO) at 9.70% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Regeneron Pharmaceuticals (REGN) at 19.99 and Thermo Fisher Scientific (TMO) at 36.64 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Regeneron Pharmaceuticals (REGN) at 2.71 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics